NeuroPace Inc (NPCE) research
NeuroPace Inc- Sector
- Healthcare
- Industry
- Medical Devices
- Last price
- $12.70
- As of
NeuroPace Inc (NPCE): 5 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-08-11.
As of . Source: SEC EDGAR filings for NPCE. Method and limitations.
Share the NPCE intelligence card
See the full NPCE dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for NPCE on one page. Preview it with sample data, then open it live with a free account.
Preview the NPCE dossierActive signals for NPCE
- mediumEARNINGS_BEAT
Q2-2026: Beat consensus by 16.5%, EPS $-0.18 vs $-0.2155 estimate
- highINSTITUTIONAL_SURGE
D. E. Shaw & Co., Inc. added +269% to NPCE (2026Q2)
- highINSTITUTIONAL_EXIT
TWO SIGMA INVESTMENTS, LP cut 59% of NPCE (2026Q2)
- highINSTITUTIONAL_SURGE
Point72 Asset Management, L.P. added +517% to NPCE (2026Q1)
- highINSTITUTIONAL_EXIT
MILLENNIUM MANAGEMENT LLC cut 57% of NPCE (2026Q1)
FREE, NO ACCOUNT
Every signal on NPCE, as it fires
You are seeing 5 of 11 signals recorded on NPCE since 2026-05-17.
The five above landed across 3 days. The other 6 were recorded on 2 other days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in NPCE (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| D. E. Shaw & Co., Inc.CUSIP 641288105 · 2026Q2 | $2.6M | 0.00% | , |
| CITADEL ADVISORS LLCCUSIP 641288105 · 2026Q2 | $2M | 0.00% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 641288105 · 2026Q2 | $1.8M | 0.00% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 641288105 · 2026Q2 | $487K | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 641288105 · 2026Q2 | $480K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, NPCE
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
NPCE against its peers
NPCE's operating margin of -16.3% ranks in the 61st percentile of 21 Medical Devices sub-industry peers, fiscal periods ending between 2025-12-28 and 2026-06-30.
| Metric | NPCE | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 100.0M USD | 85.3M USD | 57 | 21 |
| Gross margin | 77.2% | 70.9% | 60 | 20 |
| Operating margin | -16.3% | -25.5% | 61 | 21 |
| Net margin | -21.5% | -27.7% | 52 | 21 |
| Return on equity | -112.8% | -19.1% | 12 | 20 |
| P / E | n/a | 25.8x | n/a | 6 |
Peers (22): TCMD, SENS, MASS, DCTH, OFIX, RCEL, KIDS, SSII, CLPT, VMD, QSI, CV, CATX, LAB, TMCI, QDEL, TLSI, INFU, INMD, SIBN, ELMD, CBLL. Left out: BWAY (period gap), MOBI (no annual filing), PROF (no annual filing). Fiscal periods ending between 2025-12-28 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (NPCE: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more NPCE signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to NPCEand get the insider, 13F, options, and confluence read in one view.